Funkčné zobrazovacie metódy ako metabolická alternatíva biopsie: PET/CT s ¹⁸F fluorodeoxyglukózou pri gastrointestinálnom stromálnom tumore

Česká verzia

Authors: Soňa Balogová () ^1,2; Denis Viglietti () ²; Anne-Marie Tardivel () ²; Lucia Kaliská () ³; Marika Vereb () ⁴; Marek Bartovic () ¹; Dušan Cích () ¹; Vladimír Pročka () ¹; Ľudovít Lukáč () ⁵
Authors place of work: Klinika nukleárnej medicíny LF UK a OÚSA Bratislava, Slovensko ¹; Klinika nukleárnej medicíny nemocnice Tenon AP-HP & Université Pierre et Marie Curie, Paríž, Francúzsko ²; Inštitút nukleárnej a molekulárnej medicíny Košice, pracovisko Banská Bystrica, Agel diagnostics s. r. o., Slovensko ³; Oddelenie nukleárnej medicíny Reimanus s. r. o., Prešov, Slovensko ⁴; I. Interná klinika LF UK a UNB, Bratislava, Slovensko ⁵
Published in the journal: NuklMed 2012;1:68-74
Category: Casuistry

Summary

The usefulness of F-18 fluorodeoxyglucose (FDG) PET/CT in different clinical settings of many malignancies is well documented.

Early evaluation of therapeutic response by means of functional imaging providing important predictive and prognostic information is particularly interesting. Furthermore, certain anticancer agents show significant therapeutic specificity for certain types of malignancies and therapeutic test evaluated by functional imaging may serve as metabolic surrogate for histology (“metabolic biopsy”).

Gastrointestinal stromal tumours (GIST) are FDG avid mesenchymal tumours, in most cases well responding to treatment by thyrosine-kinase inhibitors (imatinib mesylate, sunitinib maleate). Therapeutic test by imatinib mesylate evaluated by FDG PET/CT may potentially serve as a “metabolic biopsy” in patients presenting tumour evocative of GIST.

This article illustrates the potential role of a “metabolic biopsy” in routine management of patients with abdominal tumour evocative of GIST.

Key Words:
PET/CT, radiation absorbed dose, eye lens

Zdroje

1. Wahl RL, Jacene H, Kasamon Y et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(S1):122S-50S

2. Stroobants S, Goeminne J, Seegers M et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20

3. Heinicke T, Wardelmann E, Sauerbruch T et al. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res 2005;25:4591-4

4. Contractor KB, Aboagye EO. Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 2009;50(S1):97S-105S

5. Imatinib mesylát, SPC www.sukl.sk

6. Sunitinib maleát, SPC www.sukl.sk

7. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82

8. RECIST 1.1. www.recist.com

9. Montravers F, Grahek D, Kerrou K et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors ? J Nucl Med 2006;47:1455-62

10. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008;13(S2):4-7

11.Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-9

12. Went PT, Dirnhofer S, Bundi M et al: Prevalence of Kit expression in human tumors. J Clin Oncol. 2004;22:514-22

13.Cristofanilli M, Morandi P, Krishnamurthy S et al: Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol 2008; 19:1713-9

14. Modi S, Seidman AD, Dickler M et al: A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 2005;90:157-63

15. Ugurel S, Hildenbrand R, Zimpfer A et al: Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398-405

16. Wyman K, Atkins MB, Prieto V et al: Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005-11

17. Einhorn LH, Brames MJ, Heinrich MC et al: Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing Kit. Am J Clin Oncol 2006;29:12-3

18. Krug LM, Crapanzano JP, Azzoli CG et al: Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 2005;103:2128-31

19. Dy GK, Miller AA, Mandrekar SJ et al: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005;16:1811-6

20. McArthur GA, Demetri GD, van Oosterom A et al: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-73

21. Bui BN, Blay JY, Bonichon F et al. Recommandations pour la pratique clinique. Standards, Options et Recommandations 2006. Prise en charge des patients adultes atteints de sarcome des tissus mous, de sarcome utérin ou de tumeur stromale gastro-intestinale. Oncologie 2007;9:173-7

22. Bourguet P, Blanc-Vincent MP, Boneu A et al. Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET scanning) in oncology (2002). Br J Cancer 2003;89(S1):84-91

23. Meda BA, Buss DH, Wooruff RD et al. Diagnosis and subclassification of primary and recurrent lymphoma. Am J Clin Pathol 2000; 113:688-99

24. Demurtas A, Accinelli G, Pacchioni D et al. Utility of flow cytometry immunophenotyping in fine-needle aspirate cytologic diagnosis of Non-Hodgkin lymphoma: A series of 252 cases and review of the litterature. Diagn Cytopathol 2006;34:472-478

25. Core Summary of product characteristics: FDG [online]. Dostupné na: ttp://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Product_Information/Core_SPC_PL/Core_SPCs/Core_SPC_FDG_2005_03.pdf